Also known as: Swiss cannabis equity programs · cannabis reparations in Switzerland

Cannabis Social Equity Programs in Switzerland

Switzerland's pilot trials are public-health studies, not social equity or restorative-justice programs.

Sourced and fact-checked
6 cited sources
Published
Last reviewed
How this page was made

This article is general information, not legal advice. Laws change; check current rules with official sources or a lawyer.

↯ The honest take

Switzerland has decriminalized small amounts of cannabis and runs time-limited pilot sales trials in several cities. But it has no 'social equity program' in the American sense — no licensing preferences, fee waivers, or reinvestment for people harmed by prohibition. The pilots are data-collection exercises, not restorative-justice mechanisms. Switzerland's policy tradition favors universalist public-health framing over targeted group reparations.

What 'social equity' means, and why Switzerland doesn't have it

In the United States, cannabis social equity programs are statutory systems that grant licensing preference, fee waivers, technical assistance, or community reinvestment funding to people and neighborhoods disproportionately harmed by cannabis prohibition [1]. Examples include Illinois's Social Equity Applicant program and New York's Conditional Adult-Use Retail Dispensary (CAURD) license [2].

Switzerland has no equivalent. The country has not created a commercial adult-use cannabis market, so no licenses exist to allocate on an equity basis. Instead, Switzerland operates a framework for time-limited scientific pilot trials, administered under Article 8b of the Narcotics Act Strong evidence. These pilots test regulated cannabis sale in restricted geographic and participant settings, but they are consumer-focused public-health studies, not restorative-justice mechanisms. None offer priority access, licensing, fee relief, or community reinvestment tied to prior cannabis convictions or historic harms of prohibition Strong evidence.

On 15 May 2021, the Swiss Federal Assembly amended the Narcotics Act (Betäubungsmittelgesetz, BetmG) to add Article 8b, establishing a legal basis for time-limited scientific pilot trials of restricted, non-medical cannabis use [3]. The amendment entered into force immediately; detailed rules are set out in the Verordnung über Pilotversuche nach dem Betäubungsmittelgesetz (BetmPV), also in force since 15 May 2021 [4].

Federal requirements under BetmPV:

None of these federal provisions reference prior convictions, socioeconomic hardship, or historic harms of prohibition as eligibility or preference criteria Strong evidence.

Active and approved pilot trials

As of October 2026, multiple cantons have launched or advanced approved pilots Strong evidence:

Some pilots include design choices that reflect harm-reduction thinking — for instance, Zurich's Züri Can incorporates non-profit cannabis social clubs, and pricing is set to undercut the illicit market Weak / limited. However, these design features are consumer-protection and market-displacement measures, not equity or reparative programs. None of the trials offer priority enrollment, licensing pathways, fee subsidies, or reinvestment funds tied to prior cannabis convictions or systemic disadvantage Strong evidence.

Expungement and criminal records

Switzerland has no federal cannabis-specific expungement or record-relief program. Since 1 October 2013, adult possession of up to 10 grams of cannabis has been decriminalized and is punishable only as a minor infraction with a CHF 100 fine under Article 28b of the Narcotics Act Strong evidence. Consumption itself remains a punishable contravention.

Criminal records for cannabis convictions from before 2013 are governed by ordinary rules on record deletion in the Strafregisterverordnung (Criminal Records Regulation), not by any cannabis-specific relief mechanism Strong evidence. Advocacy groups including Legalize it! and the industry association IG Hanf have publicly called for both a regulated market and record relief, but as of October 2026, no bill combining the two has advanced in parliament.

Potential future regulated market

Since 2023, a subcommission of the parliamentary Commission for Social Security and Health (SGK-N) has been drafting a proposal for a fully regulated adult-use cannabis market, informed by pilot trial data [6]. Publicly available drafts and media coverage suggest the model under discussion emphasizes:

Whether any future law will incorporate US-style social equity provisions — such as licensing priority for people with prior cannabis convictions, community reinvestment funds, or set-asides for small growers — remains unknown No data. Switzerland's policy tradition leans toward universalist public-health framing rather than group-targeted reparative or restorative-justice programs, which may make direct adoption of the American equity model unlikely.

This article is informational only and is not legal advice. Cannabis law in Switzerland changes at both federal and cantonal levels; pilot rules differ by municipality. Participation eligibility, legal status, and enforcement vary. If you need to know whether a specific activity is lawful in your location, consult a qualified Swiss attorney or contact the Federal Office of Public Health (BAG/OFSP) directly.

Last verified: October 31, 2026.

Sources

How this page was made

Generation history

Jul 25, 2026
Fact-check pass — raised 5 flags
Oct 31, 2026
Revision
Jul 26, 2026
Fact-check pass — raised 2 flags
Jul 26, 2026
Initial draft

Drafting assistance and fact-check automation are used, with a human operator spot-checking on a weekly basis. See how articles are made.